VNX 101
Alternative Names: VNX-101Latest Information Update: 17 Sep 2024
At a glance
- Originator Vironexis Biotherapeutics
- Class Antineoplastics; Gene therapies; Immunoglobulin Fv fragments; Immunotherapies
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 12 Sep 2024 US FDA approves IND application for VNX 101 for the treatment of Precursor B-cell lymphoblastic leukaemia-lymphoma
- 12 Sep 2024 US FDA grants Rare Pediatric Disease Designation (RPDD) to VNX 101 for Precursor B-cell lymphoblastic leukaemia-lymphoma in USA
- 12 Sep 2024 VNX 101 receives Fast Track designation for Precursor B-cell lymphoblastic leukaemia-lymphoma [IV-infusion] in USA